Shares of Tempus AI slid 5.1% to $46.95 on May 8, extending a punishing 16% decline from their May 1 close of $55.00 — even as the broader Nasdaq rallied 1.24%. The precision-medicine company grew Q1 revenue 36.1% to $348.1 million, lifted gross margin to 63.8%, and raised 2026 revenue guidance to $1.59–$1.60 billion . The selloff tells a story about what Wall Street demands from high-growth, money-losing AI companies — and the price of falling even slightly short.
The Revenue Miss Stung More Than the Earnings Beat Helped. Tempus posted an adjusted loss of -$0.13 per share, beating the roughly -$0.20 consensus . But revenue of $348.1 million only narrowly topped the $345.4 million analyst estimate — not the blowout investors expected from a stock priced for perfection. For a company still burning cash, every missed dollar of top-line growth raises questions about how fast it can reach breakeven.
A $400 Million Debt Deal Added Dilution Fears at the Worst Time. Just two days after earnings, Tempus priced an upsized $400 million offering of convertible senior notes — bonds that can later convert into stock, potentially diluting existing shareholders. Proceeds will repay $307.7 million in secured loans , cleaning up the balance sheet but signaling that management sees low stock prices as an acceptable trade-off for cheaper long-term debt. The notes carry a 0.00% interest rate , an extraordinary term that underscores investor appetite for upside equity exposure — but also piles on conversion risk.
The GAAP Losses Keep Growing, Even as Adjusted Numbers Improve. The GAAP net loss ballooned to $125.9 million, up from $68.0 million a year ago, swollen by $56.3 million in stock-based compensation and $32.3 million in unrealized securities losses . On an adjusted basis, the net loss improved to $22.6 million and adjusted EBITDA — a rough measure of operating cash profitability — shrank to a loss of just $2.8 million . The gap between these two realities is widening, and investors are deciding which version of the story to believe.
Big Pharma Deals Signal Staying Power, But Profits Remain Distant. Tempus is shifting from one-off data licensing projects to multi-year strategic collaborations exceeding $100 million in total contract value , including new partnerships with Merck and an expanded Gilead relationship . Management projects the Q1 EBITDA loss of $3 million will flip to a $65 million gain for the full year as back-half data contracts kick in. That's a compelling forecast — if it materializes. Until then, the stock's ~15% haircut this week is a reminder that in today's market, growth without proof of profits gets punished fast.